BEACON - A Phase II Study of Bevacizumab, Atezolizumab and Cobimetinib in Targeting the C1 Subtype of High Grade Serous Ovarian Cancer

Trial Profile

BEACON - A Phase II Study of Bevacizumab, Atezolizumab and Cobimetinib in Targeting the C1 Subtype of High Grade Serous Ovarian Cancer

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Cobimetinib (Primary)
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Acronyms BEACON
  • Most Recent Events

    • 08 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top